Abstract
It has been suggested, based on rodent studies, that levodopa (L-dopa) induced dyskinesia is associated with a disrupted blood-brain barrier (BBB). We have investigated BBB integrity with in vivo neuroimaging techniques in six 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioned primates exhibiting L-dopa-induced dyskinesia. Magnetic resonance imaging (MRI) performed before and after injection of Gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) revealed an intact BBB in the basal ganglia showing that l-dopa-induced dyskinesia is not associated with a disrupted BBB in this model.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Animals
-
Antiparkinson Agents / adverse effects*
-
Antiparkinson Agents / therapeutic use
-
Blood-Brain Barrier / pathology*
-
Brain / blood supply
-
Brain / pathology
-
Dyskinesia, Drug-Induced / pathology*
-
Gadolinium DTPA
-
Levodopa / adverse effects*
-
Levodopa / therapeutic use
-
Macaca fascicularis
-
Magnetic Resonance Imaging
-
Male
-
Parkinsonian Disorders / drug therapy*
-
Parkinsonian Disorders / pathology
-
Time Factors
Substances
-
Antiparkinson Agents
-
Levodopa
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Gadolinium DTPA